BioClad, a specialist manufacturer, supplier and installer of hygienic cladding technology is the first business of its kind to scoop a Queen’s Award for Enterprise in International Trade in this year’s honours.
The prestigious accolade reinforces the powerful reputation of the Harrogate business as a global leader in revolutionising antimicrobial hygienic spaces in sectors spanning healthcare, pharmaceutical, education, retail, and leisure.
The tribute also acknowledges how the manufacturer, which was launched in 2008 and employs 20 people, has marked a 2000 per cent growth in exporting since broadening its horizons into international trade in 2011.
Global sales account for 25 per cent of BioClad’s £10 million current turnover – an increase of £1.5 million on last year. Blazing an export trail in principal markets comprising Australia, Canada, India, Saudi Arabia, UAE and Mexico, BioClad has recently opened an Australian subsidiary in Perth and is poised to enter European markets.
With a product portfolio encompassing pvc wall cladding, floor coverings and an innovative new handwash unit, BioClad’s unique range of antimicrobial surfaces kill 99.9 per cent of microbes and protect against E.Coli, MRSA and influenza.
UK commissions include the biggest contract in the sector, for Hinkley Point C nuclear power station, Birmingham Children’s Hospital Cancer Unit and a raft of projects for changing rooms and catering facilities at leading football clubs such as Leeds United and Liverpool.
Fast food giants Five Guys, Costa Coffee and McDonald’s are among BioClad’s high-profile international clients.
Founder and director Lindsay McKenzie said: “This globally-recognised and highly respected seal of approval is a powerful endorsement of our successful strategy in harnessing the wealth of international trade opportunities while successfully delivering wide-ranging domestic commissions. An enormous ‘thank you’ to our talented and committed team for being instrumental in making this happen.
“With the global flooring market predicted to be worth $300 billion by 2020, and no other company producing this type of antimicrobial surface, the world is literally our oyster as we embark on the next stage of our journey.”